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Abstract In the past four decades, chemoprevention of
colorectal cancer (CRC) has been the subject of many
epidemiologic and intervention trials of naturally occurring
or pharmacologic agents. Recently, the positioning of
cyclooxygenase 2 inhibitors as a viable option in this
context was a major breakthrough; however, it was
hampered by adverse cardiovascular events. This review
questions whether chemopreventive measures for CRC are
ready to be used in mass or individual applications,
standing alone or in combination with other CRC-
preventive measures. It also discusses steps that may be
undertaken to explore this field further.
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Introduction
The task of this overview can be resolved easily or not at
all. If we want to understand chemoprevention of colorectal
cancer (CRC) as either the administration of favorable
chemical agents (natural or synthetic) or the exclusion of
adversely acting compounds, we would be able to indicate
an effect on nearly every human subject, even if the
individual gain is very small. On the contrary, if we aim at a
significant, well-defined, and tangible CRC-preventive
effect in individual patients with normal or high risk for
the occurrence of precancerous or cancerous colorectal
lesions, the outcome may be poor or at least very
unreliable. However, for both options there are ways to
develop and—together with nonchemical intervention—
provide quite effective CRC prevention now. We can
consider primary, secondary, and tertiary prevention in this
context.
Should We Aim at a Mass Effect?
If we want a mass effect of CRC prevention, we would, for
example, consider preventive actions in populations with a
high incidence and considerable lifetime risk of developing
CRC (eg, about 6% in the Western world) [1]. Some
“chemical” risk factors or risk situations are clearly defined
in this context, including the nutritional causes of the
metabolic syndrome, which is associated with a risk of
CRC as well as many other malignancies [2]. Let us be
clear: if the overnutrition of a large proportion of certain
populations had been avoided some decades ago and if
adequate dietary and lifestyle advice had been given at an
early stage, Western medicine could have stopped the surge
of CRC that is still occurring in several countries. If such
actions had been combined with a reduction in tobacco use,
we would have saved many lives and immense sums in
health care expenses (including those necessary for forming
armies of endoscopists, nurses, and other health care
workers).
Fortunately, it is not too late for action: applying such
measures to large uninformed and innocent populations,
such as children and those in underdeveloped or
developing countries who are repeating the mistakes of
Western cultures, might at least partly reduce our feel-
ings of professional failure and guilt. We must acknowl-
edge that being a physician today involves much more
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in the widest sense is a “must,” not only ethically but
also economically.
Reversing the process of latent colorectal carcinogen-
esis in populations composed of both healthy- and
unhealthy-living individuals by adding one or several
defined chemical substances to their diet carries much
promise. However, in the proportion of these populations
with high lifestyle risks for precancerous or cancerous
lesions, the critical time point for reversing carcinogenic
mechanisms may already have passed, and intervention
may give few or no results. Most intervention studies
performed in these populations and using vitamins, fiber,
and other agents showed either no or marginal effects.
Whether adding synthetic and stronger CRC-preventive
compounds can improve the prognosis of such groups
with respect to CRC has, to my knowledge, not yet been
studied and certainly cannot be excluded. Trials examin-
ing this question—either prospective or retrospective—
would necessitate clear definitions of healthy and
unhealthy lifestyles and would require huge numbers of
participants and/or lengthy study periods. Once studies are
undertaken, they should include outcome parameters
regarding not only CRC, but also other malignant or
benign disorders.
CRC Chemoprevention for High-Risk Patients
Should we offer CRC chemoprevention to patients at
very high risk? Of course we should. These are the
patients who have undergone successful CRC treatment
(tertiary prevention), those who have had adenomatous
polyps removed (secondary prevention), and those at
high risk because of accumulated risk factors—lifestyle,
genetic, and hereditary—(primary prevention). Patients
at high risk also include, in extreme cases, those with
familial adenomatous polyposis, for whom there already
is a US Food and Drug Administration-approved
indication for the use of cyclooxygenase 2 (COX-2)
inhibitors [3••]. In the risk/effect calculation, we would
need agents with considerable proven effect and safety
margins that could guarantee a significant health gain in
small populations. These types of preventive interventions
are similar to drug therapies for non-malignant and less
severe disorders, for which we are prone to accept adverse
effects to a certain degree if the net effect is convincing,
such as in the use of aspirin to prevent cardiovascular
fatalities [4]. However, there are experts who argue that
“preventive actions” should never be harmful. The balance
between the chances of benefit and harm in these
situations should always be discussed with patients in a
clear and straightforward way. Also, besides approval by
the institutions responsible for drug indications, patients’
informed consent must be obtained and documented. Such
consent should be obtained only after patients have been
offered a thorough explanation of the advantages and
disadvantages of the current “gold standard” in CRC
screening, that is, optical colonoscopy with the eventual
endoscopic removal of precancerous and minor cancerous
lesions.
Colonoscopy: The Mainstay of CRC Prevention
Many methods are currently available for detecting prema-
lignant and malignant lesions of the colon, and new ones
are on the way [5]. These methods range from optical
techniques (x-ray, CT, MRI, manual high-resolution colo-
noscopy, and semiautomated colonoscopy) to biochemical,
immunologic, and genetic tests of feces or blood. None of
the latter (non-imaging) methods is accurate enough yet to
detect colorectal neoplasia within the necessary range of
sensitivity and specificity. In the imaging field, trials and
discussions are ongoing to determine whether virtual
colonoscopy with CT (CT colonography) can be used to
select participants for screening with optical colonoscopy
with the possibility of removing any “real” lesions
discovered [6]. The semiautomated endoscopic approaches
are still under study for the same purpose. However, one
must realize that even with the best available techniques,
total optical colonoscopy with biopsies and/or other
methods of removal (snare polypectomy, mucosectomy)
remains a necessity for solving the problem, notwithstand-
ing the discomfort and adverse effects this method may
have, even in the hands of the best-trained endoscopists. It
is estimated that about 40% of screening CTcolonographies
result in a positive or doubtful finding requiring optical
colonoscopy [7].
Unfortunately, campaigns for CRC screening pay too
little attention to the fact that the most frequently used non-
imaging screening method—the fecal occult blood test
(FOBT), as well as its advanced immunologic version
(iFOBT)—has a sensitivity for invasive CRCs of 70% or
less, and that the sensitivity is much lower for precancerous
lesions, otherwise known as advanced neoplasia (< 30%)
[8]. Comparing these relatively low figures with the
estimated (unfortunately, not yet prospectively proven)
possibility of reducing CRC mortality by more than 80%
with primary colonoscopy and lesion removal, with an
examination every 10 years after the age of 50 [9], should
lead to the conclusion that—in CRC screening programs—
optical colonoscopy should always be one of the options
provided to screenees, even if less invasive methods have
been selected for the majority of the population for
economic or organizational reasons.
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Having clarified that none of the presently available methods
for CRC prevention can reach a result comparable with
optical detection and instrumental removal of colorectal
neoplasia, the following questions must be answered:
1. Is a combination of chemoprevention and colonoscopy
advisable? If so, in which design?
2. Are there suitable compounds for the chemoprevention
part of such a combination?
3. How do we characterize or identify people who would
benefit from a combination strategy?
Combination Colonoscopy and Chemoprevention
It is obvious that—for now and in the near future—neither
general nor individual chemoprevention with lifestyle-
related and/or pharmacologic chemoprevention can replace
optical examination of the colon if the objective is early
detection or prevention of CRC. The recently published
forerunner trials performed with COX-2 antagonists have
clearly indicated that a partial reduction in recurrent colonic
adenomas (by about 30% to 40%) is possible for at least
3 years [10••], but at the cost of considerable cardiovascular
adverse effects [11]. Even if this strategy had been
approved by national or international health authorities,
the trials performed did not give a secure clue about
individual screenee characteristics that would predict a
potential benefit from the pharmacologic intervention,
precluding prospective selection for such a combined
strategy. Compared with the very precise pharmacologic
studies testing the value of COX-2 inhibitors, an assump-
tion of the effect of lifestyle-related chemoprevention on
individual screenees must remain even more approximate
or—clearly spoken—impossible. Accepting these facts,
there is still a need to identify safer and more effective
chemoprevention methods and to retest them in trials using
colonoscopic assessment of the outcome, as was done in
the aforementioned experiments with COX-2 inhibitors.
Candidates for CRC Chemoprevention in the Near Future
Based on the available knowledge from human and animal
studies, there is a limited number of agents available for
further testing, either alone or in different combinations
[3••]. They will be based mostly on experience gained from
controlled epidemiologic and/or intervention studies or
from animal models, and might combine reduced doses of
known pharmacologic agents (eg, aspirin or COX-2
inhibitors) with other promising compounds, such as
selenium or curcumin [3••, 12]. However, before controlled
human studies can be performed, it will take more than
single short-term animal experiments to avoid the immense
investment of human and economic resources necessary to
develop more effective and safer versions of CRC chemo-
prevention. In this context, using previously adopted
protocols and procedures, such as those of the PreSAP
(Prevention of Colorectal Sporadic Adenomatous Polyps)
and APC (Adenoma Prevention With Celecoxib) trials
[10••, 11], would improve comparability of outcomes.
Identifying the Screenees to be Targeted for a Combined
Colonoscopy/Chemoprevention Strategy
On the basis of existing scientific evidence, it is impossible
to identify the individuals or populations that, with any
certainty, could be directed to a combined CRC colono-
scopy/chemoprevention strategy. Identification of target
group characteristics for a similar approach should be part
of any future testing of chemopreventive agents and should
include biological as well as psychological and social
factors with a potential impact. Also, biological material
from participants in such trials should be obtained and
preserved (ie, bio-banked), because possible “markers” for
the susceptibility, tolerability, and economic utility of future
chemopreventive options may potentially be investigated
with the help of such preserved material.
In the Meantime
It is frustrating not to have an answer to the question of who
would benefit from CRC chemoprevention without risking
insufficient efficacy and/or hazardous side effects. At present,
attempts in this direction might result in professional—
including legal—consequences. In considering any patient
for chemopreventive alternatives to the accepted (“conven-
tional”) CRCscreeningmethods, one mustclearlyaccount for
the statistical validity of such measures, albeit with an
explanation of evidence lacking for individual applicability.
Also,inlightofthepresentgoldstandardforCRCprevention,
one should consider how to proceed with a patient at high risk
for CRC who refuses a screening colonoscopy (or has relative
or absolute contraindications for it) in the setting of clinical
indications or a high suspicion of CRC based on any non-
colonoscopic screening method. In this difficult situation,
many patients and their medical advisers would reconsider
and choose the option of colonoscopy, asking for the best
available standards of preparation, technique, and follow-up.
Conclusions
The presently available lifestyle-related or chemopreventive
options against CRC still have low or moderate efficacy
46 Curr Colorectal Cancer Rep (2010) 6:44–47compared with the current gold standard of optical colono-
scopy and lesion removal. The most promising substances for
chemoprevention—COX-2 inhibitors—were not approved
for CRC chemoprevention because of adverse cardiovascular
events. Future therapies should be tested with a comparable
accuracy to avoid failure and/or negative side effects in
persons and populations subjected to them. In the meantime,
the quality of colonoscopy-based screening and follow-up
procedures should be improved and adequate focused
information regarding the population considered for CRC
prevention should be provided to prevent further delays in the
fight against this potentially avoidable malignancy.
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